Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empower the Heart of Patients with Terminal Cancer using Cardiac Medicines Trial
2021-006994-48Phase 2Completed
- Sponsor
- Universitätsmedizin Essen
- Start
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of sacubitril + valsartan, ferric carboxymaltose, empagliflozin and ivabradine in cancer, heart failure (HF), anaemia and 1 more, sponsored by Universitätsmedizin Essen. Primary endpoint: Days alive and able to wash themselves. Started Jan 2022; status: completed.
02
Drugs
sacubitril + valsartanferric carboxymaltoseempagliflozinivabradine
03
Conditions
cancerheart failure (HF)anaemiacardiometabolic disease
Beyond the preview
Go deeper on 2021-006994-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006994-48.